Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel

JAMA

Volumn 277, Issue 24, 1997, Pages 1962-1969

  Carpenter, Charles C J ^a,n   Fischl, Margaret A ^b   Hammer, Scott M ^c   Hirsch, Martin S ^c   Jacobsen, Donna M ^d   Katzenstein, David A ^e   Montaner, Julio S G ^f   Richman, Douglas D ^g   Saag, Michael S ^h   Schooley, Robert T ⁱ   Thompson, Melanie A ^j   Vella, Stefano ^k   Yeni, Patrick G ^l   Volberding, Paul A ^m  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d International AIDS Society USA   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f ST PAUL S HOSPITAL   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j AIDS Research Consortium of Atlanta   (United States)

^k ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^l BICHAT HOSPITAL   (France)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ BROWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL PROTOCOL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PERINATAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT PLANNING; VIRUS TITRATION; VIRUS TRANSMISSION;

EID: 0030979361     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.24.1962     Document Type: Article

References (61)

1. Carpenter CCJ, Fisehl MA, Hammer SM, et al, for the International AIDS Society-USA. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996; 276:146-154.
2. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358.
3. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:359-362.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
5. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1. Nature. 1995;373:117-122.
6. Perelson AS, Neuman AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science. 1996;271:1582-1586.
7. Cohen OJ, Pantaleo G, Holodniy M, et al. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects down-regulation of viral replication in lymphoid tissues. Proc Natl Acad Sci U S A. 1995;92:6017-6021.
8. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med. 1995;332:209-216.
9. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985-989.
10. Boswell SL, Mayer KH, Goldstein RS, Tucker L, Xu C, Anderson D. The effect of HIV protease inhibitors on seminal proviral DNA. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 202.
11. Pialoux G, Fournier S, Moulignier A, Poveda JD, Clavel F, Dupont B. Central nervous system as sanctuary of HIV-1 in a patient treated with AZT + 3TC + indinavir. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26,1997; Washington, DC. Abstract 233.
12. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of HIV-1 infected men at all stages of disease and its reduction by antiretroviral therapy. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 726.
13. Lennox J, Ellerbrock T, Palmore M, et al. Effect of antiretroviral therapy on vaginal HIV RNA level. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 727.
14. Mellors JW, Kinsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995; 122:573-579.
15. Katzenstein DA, Hammer SM, Hughes MD, et al, for the AIDS Clinical Trials Group Study 175 Virology Study Team. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells/μL. N Engl J Med. 1996;335:1091-1098.
16. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105-110.
17. Mellors JW, Kingsley L, Gupta P, et al. Prognostic value of plasma HIV-1 RNA quantification in seropositive adult men. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract We.B.410.
18. Hammer SM, Katzenstein DA, Hughes MD, et al, for the AIDS Clinical Trials Group Study 175 Study Team. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500/μL. N Engl J Med. 1996;335:1081-1090.
19. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis. 1996; 174:704-712.
20. Welles SL, Jackson JB, Yen-Lieberman B. Prognostic value of plasma HIV-1 RNA levels in patients with advanced HIV-1 disease and with little or no zidovudine therapy. J Infect Dis. 1996;174:696-703.
21. + lymphocyte counts and the risk of progression to AIDS: Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426-431.
22. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med. 1996; 2:625-629.
23. Brichacek B, Swindells S, Jannoff E, Pirrucello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with vaccine. J Infect Dis. 1996;174:1191-1199.
24. Staprans SL, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J Exp Med. 1995;182: 1727-1737.
25. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995;86: 1082-1089.
26. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers-are we being naive? J Infect Dis. 1997;175:237-245.
27. Mellors JW. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
28. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. In press.
29. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science. 1996;273:1856-1861.
30. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
31. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV in blood and lymph nodes after potent antiretroviral therapy. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract LB10.
32. Gulick RM, Mellors JW, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV), and lamivudine (3TC). In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.931.
33. 3. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-27, 1997; Washington, DC. Abstract LB7.
34. Powderly WG, Sension M, Conant M, Stein A, Clendeninn N. The efficacy of Viracept (nelfinavir mesylate, NFV) in pivotal phase I/II double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-27, 1997; Washington, DC. Abstract 370.
35. Markowitz M, Cao Y, Vesanen M, et al. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-27, 1997; Washington, DC. Abstract LB8.
36. 3. In: Programs and abstracts of the 8th Congress of Clinical Microbiology and Infectious Diseases; May 25-28, 1997; Lausanne, Switzerland. Abstract 90A.
37. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract LB6a.
38. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus HIVID (zalcitabine, ddC). In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract LB.B.6033.
39. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996;173:321-329.
40. + T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997;3:533-540.
41. Coffin JM. Population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science. 1995;267:483-489.
42. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283-291.
43. + cells per cubic millimeter. N Engl J Med. 1996;335:1099-1106.
44. Ho DD. Can HIV be eradicated? In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-27, 1997; Washington, DC. Abstract S1.
45. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:145-153.
46. + cell counts 200-600μL. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Mo.B.294.
47. + cell counts of 200-600/μL. In: Program and abstracts of the Third International Congress on Drug Therapy in HIV Infection; November 3-7, 1996; Birmingham, England. Abstract OP7.1.
48. Wainberg MA, Birch C, for the Boehringer-Ingelheim 1046 Study Team (INCAS trial). Phenotypic and genotypic resistance emergent in naive HIV-1 patients treated with combinations of reverse transcriptase inhibitors. In: Program and abstracts of the Third International Congress on Drug Therapy in HIV Infection; November 3-7, 1996; Birmingham, England. Abstract OP7.2.
49. Cohen C, Sun E, Cameron W, et al. Ritonavirsaquinavir combination treatment in HIV-infected patients. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans, La. Abstract LB7b.
50. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR Trial. Lancet. 1997;349:1413-1421.
51. Staszewski S, Bartlett J, Hill AM, Katlama C, Johnson J. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS. 1997;11:474-483.
52. Katlama C, Valentin MA, Calvez S, et al. ALTIS: a pilot open study of d4T/3TC antiretroviral naive and experienced patients. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-27, 1997; Washington, DC. Abstract LB4.
53. Pollard R, Peterson D, Hardy D, et al. Antiviral effect and safety of stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blind trial. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 196.
54. Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet. 1997; 349:1408-1409.
55. Centers for Disease Control and Prevention. Update: provisional recommendations for chemoprophylaxis after occupational exposures to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1996;45:468-472.
56. Panel on Clinical Practices for Treatment of HIV Infection, the US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Federal Register. In press.
57. Connor EM, Sperling RS, Gelber R, et al, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331:1173-1180.
58. Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of the human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis. 1996; 174:1207-1211.
59. Centers for Disease Control and Prevention. AIDS among children-United States, 1996. MMWR Morb Mortal Wkly Rep. 1996;45:1006-1010.
60. Sperling RS, Shapiro DE, Coombs RW, et al, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335:1621-1629.
61. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA. 1996;275:1483-1488.